Research
Hormonal
Semaglutide is safe and effective for weight loss in obese, non-diabetic patients with end-stage kidney disease on haemodialysis.
Practitioners may consider semaglutide as a treatment option for weight loss in similar patient populations.
StrongSupportsmedium confidence
The following cases demonstrate a proof of concept for the safe and effective use of the glucagon-like-peptide-1 receptor agonist (GLP-1 RA) semaglutide for weight loss in obese, non-diabetic, end stage kidney disease (ESKD) patients on haemodialysis (HD).
Why this rating
The findings are based on case reports demonstrating significant outcomes.
Source
Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end‐stage‐kidney‐disease
Rory Wallace et al. · Nephrology · 2024
DOI 10.1111/nep.14277
case_study · n=2Cited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →